Why do PD trials keep failing? Seven solutions for neuroprotection скачать в хорошем качестве

Why do PD trials keep failing? Seven solutions for neuroprotection

Etienne Hirsch, PhD, Institut du Cerveau-ICM, Inserm, Sorbonne Université, Paris, France, outlines seven solutions for neuroprotection in Parkinson’s disease (PD), which he presented in the C. David Marsden presidential lecture at the Movement Disorder Society congress 2021. Despite a plethora of attempted strategies and much preclinical success,, no neuroprotective agent has demonstrated efficacy in clinical trials. Prof. Hirsch shares seven reasons why these trials may have been unsuccessful and how we can change our approach for successful development of neuroprotective drugs. These include selecting defined patient subgroups in which the targeted mechanism is involved in the pathological process, intervening earlier in the disease course, improving drug delivery to the appropriate brain regions, combining treatments that target different disease mechanisms, and considering variation in disease mechanisms throughout the disease course. This interview took place during the 2021 International Congress of Parkinson's Disease and Movement Disorders.